Investors sound alarm about pending drug pricing legislation

A quarter of a century ago, the threat of government price controls panicked investors, sparking a flight from the pharma sector that almost strangled the biotech industry in its infancy. Investors and biopharma executives, including many who survived the Clinton healthcare plan 26 years

Read the full 445 word article

User Sign In